newsfilter
← Latest News
GlobeNewswire·

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents, and